Systemic lupus erythematosus in Asturias, Spain: clinical and serologic features - PubMed (original) (raw)

Systemic lupus erythematosus in Asturias, Spain: clinical and serologic features

Jesús Gómez et al. Medicine (Baltimore). 2006 May.

Free article

Abstract

Asturias is an autonomous region in the north of Spain with historical and anthropologic peculiarities. In the current report, we examine the main clinical and immunologic features of 363 patients with systemic lupus erythematosus (SLE), virtually the entire population of SLE patients in Asturias. We constructed a database with the clinical and immunologic features of all patients fulfilling the American College of Rheumatology criteria, based on the review of hospital records corresponding to blood samples received for antinuclear antibodies testing since 1992. Arthritis was the most frequently observed main clinical feature and neuropathy was the rarest. Male patients had a disease more frequently characterized by serositis (p<0.05) and neurologic disorder (p<0.01) than females, while children presented malar rash (p<0.05), fever (p<0.05), and kidney involvement (p<0.01) more often than adults. Late-onset patients were characterized by lower frequencies of malar rash (p<0.01), neurologic disorder (p<0.05), alopecia (p<0.01), and lymphadenopathy (p<0.05) than young adults. Numerous direct and inverse significant associations were found among clinical and immunologic features. The most relevant significant associations were neurologic disorder with lupus anticoagulant (p<0.01); kidney involvement with serositis (p<0.01) and DNA antibodies (p<0.05); and thrombosis with DNA antibodies (p<0.05), cardiolipin antibodies (p<0.01), and lupus anticoagulant (p<0.01). A low mortality was found in our series, although kidney involvement (p<0.05) and cardiolipin antibodies (p<0.05) are factors associated with poor survival.

PubMed Disclaimer

Cited by

Chinese Systemic Lupus Erythematosus Treatment and Research Group Registry IX: Clinical Features and Survival of Childhood-Onset Systemic Lupus Erythematosus in China.
Wu CY, Li CF, Wu QJ, Xu JH, Jiang LD, Gong L, Wu FQ, Gu JR, Zhao JL, Li MT, Zhao Y, Zeng XF; CSTAR Co-authors. Wu CY, et al. Chin Med J (Engl). 2017 Jun 5;130(11):1276-1282. doi: 10.4103/0366-6999.206346. Chin Med J (Engl). 2017. PMID: 28524825 Free PMC article.
A systematic review and meta-analysis of cutaneous manifestations in late- versus early-onset systemic lupus erythematosus.
Medlin JL, Hansen KE, Fitz SR, Bartels CM. Medlin JL, et al. Semin Arthritis Rheum. 2016 Jun;45(6):691-7. doi: 10.1016/j.semarthrit.2016.01.004. Epub 2016 Jan 21. Semin Arthritis Rheum. 2016. PMID: 26972993 Free PMC article.
Th17 responses and natural IgM antibodies are related to gut microbiota composition in systemic lupus erythematosus patients.
López P, de Paz B, Rodríguez-Carrio J, Hevia A, Sánchez B, Margolles A, Suárez A. López P, et al. Sci Rep. 2016 Apr 5;6:24072. doi: 10.1038/srep24072. Sci Rep. 2016. PMID: 27044888 Free PMC article.
Prevalence of systemic lupus erythematosus in Spain: higher than previously reported in other countries?
Cortés Verdú R, Pego-Reigosa JM, Seoane-Mato D, Morcillo Valle M, Palma Sánchez D, Moreno Martínez MJ, Mayor González M, Atxotegi Sáenz de Buruaga J, Urionagüena Onaindia I, Blanco Cáceres BA, Silva-Fernández L, Sivera F, Blanco FJ, Sánchez-Piedra C, Díaz-González F, Bustabad S; Working Group Proyecto EPISER2016. Cortés Verdú R, et al. Rheumatology (Oxford). 2020 Sep 1;59(9):2556-2562. doi: 10.1093/rheumatology/kez668. Rheumatology (Oxford). 2020. PMID: 31998955 Free PMC article.
Common and specific associations of anti-SSA/Ro60 and anti-Ro52/TRIM21 antibodies in systemic lupus erythematosus.
Menéndez A, Gómez J, Caminal-Montero L, Díaz-López JB, Cabezas-Rodríguez I, Mozo L. Menéndez A, et al. ScientificWorldJournal. 2013 Oct 30;2013:832789. doi: 10.1155/2013/832789. eCollection 2013. ScientificWorldJournal. 2013. PMID: 24294139 Free PMC article.

References

1. Abusamieh M, Ash J. Atherosclerosis and systemic lupus erythematosus. Cardiol Rev. 2004;12:267-275.
1. Beaufils M, Kouki F, Mignon F, Camus JP, Morel-Maroger L, Richet G. Clinical significance of anti-Sm antibodies in systemic lupus erythematosus. Am J Med. 1983;74:201-205.
1. Boddaert J, Huong du LT, Amoura Z, Wechsler B, Godeau P, Piette JC. Late-onset systemic lupus erythematosus: a personal series of 47 patients and pooled analysis of 714 cases in the literature. Medicine (Baltimore). 2004;83:348-359.
1. Borchers AT, Keen CL, Schoenfeld Y, Gershwin ME. Surviving the butterfly and the wolf: mortality trends in systemic lupus erythematosus. Autoimmun Rev. 2004;3:423-453.
1. Brey RL, Stallworth CL, McGlasson DL, Wozniak MA, Wityk RJ, Stern BJ, Sloan MA, Sherwin R, Price TR, Macko RF, Johnson CJ, Earley CJ, Buchholz DW, Hebel JR, Kittner SJ. Antiphospholipid antibodies and stroke in young women. Stroke. 2002;33:2396-2400.

Systemic lupus erythematosus in Asturias, Spain: clinical and serologic features - PubMed (original) (raw)